MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

A

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

9.51 2.04

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.12

Max

9.6

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

134.143

90.831

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+32.35% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 25. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-384M

1.5B

Iepriekšējā atvēršanas cena

7.47

Iepriekšējā slēgšanas cena

9.51

Ziņu noskaņojums

By Acuity

50%

50%

151 / 361 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. janv. 22:41 UTC

Iegādes, apvienošanās, pārņemšana

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

2026. g. 15. janv. 00:00 UTC

Peļņas

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

2026. g. 14. janv. 23:47 UTC

Tirgus saruna

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

2026. g. 14. janv. 23:44 UTC

Tirgus saruna

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

2026. g. 14. janv. 23:39 UTC

Tirgus saruna

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

2026. g. 14. janv. 23:32 UTC

Tirgus saruna

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026. g. 14. janv. 22:56 UTC

Iegādes, apvienošanās, pārņemšana

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

2026. g. 14. janv. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

2026. g. 14. janv. 22:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 14. janv. 22:17 UTC

Tirgus saruna

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

2026. g. 14. janv. 22:09 UTC

Peļņas

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

2026. g. 14. janv. 22:08 UTC

Peļņas

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

2026. g. 14. janv. 22:08 UTC

Peļņas

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

2026. g. 14. janv. 21:53 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

2026. g. 14. janv. 21:53 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

2026. g. 14. janv. 21:52 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Announces Positive Profit Alert for 2025

2026. g. 14. janv. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Citigroup Acting as Financial Advisor to WuXi XDC

2026. g. 14. janv. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC: Aims to Keep Listing Status of BioDlink

2026. g. 14. janv. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

2026. g. 14. janv. 21:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2026. g. 14. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 14. janv. 21:49 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC: BioDlink Offer to Cost HK$2.79B

2026. g. 14. janv. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

2026. g. 14. janv. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Makes Cash Offer for BioDlink International

2026. g. 14. janv. 21:13 UTC

Tirgus saruna

Oil Retreats Late After Trump Comments on Iran -- Market Talk

2026. g. 14. janv. 20:30 UTC

Tirgus saruna
Peļņas

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

2026. g. 14. janv. 20:13 UTC

Tirgus saruna

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

2026. g. 14. janv. 20:08 UTC

Tirgus saruna

Oil Futures Extend Rally on Iran Tensions -- Market Talk

2026. g. 14. janv. 19:33 UTC

Tirgus saruna

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

2026. g. 14. janv. 19:06 UTC

Tirgus saruna
Peļņas

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

32.35% augšup

Prognoze 12 mēnešiem

Vidējais 12.11 USD  32.35%

Augstākais 16 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

151 / 361 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat